Opendata, web and dolomites

AcTaferon

Revitalizing the clinical potential of type I IFNs in fighting influenza A virus infections with AcTaferon.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AcTaferon project word cloud

Explore the words cloud of the AcTaferon project. It provides you a very rough idea of what is the project "AcTaferon" about.

remained    mortality    affinity    miracle    drugs    industrial    limited    co    cancer    fight    substantial    huge    unveils    concentration    sensitivity    serious    tumor    vitro    desired    interferons    eacute    interdisciplinary    site    fundamental    inactive    hence    combining    route    asset    offers    health    regression    seasonal    models    strategy    actaferon    clinical    surface    influenza    infection    ifns    viral    epidemics    therapeutic    drug    prof    binding    mutant    body    uz    expertise    ifn    pilot    based    en    ing    moiety    antitumor    receptor    influence    cells    threat    recognizes    transferred    severe    broaden    vivo    academic    tackle    activated    diseases    too    morbidity    circumvents    administrable    cytokine    extend    efficient    intracellular    pipeline    opportunity    viruses    causing    cellular    obstacles    preliminary    negatively    limits    occasional    antiviral    actaferons    pandemics    respectively    innovative    receptors    underscore    effect    background    saelens    biological    interferon    fusing    doses    regulate    company    orionis    marker   

Project "AcTaferon" data sheet

The following table provides information about the project.

Coordinator
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS 

Organization address
address: RUE MICHEL ANGE 3
city: PARIS
postcode: 75794
website: www.cnrs.fr

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website https://www.cordis.europa.eu/project/rcn/209395_en.html
 Total cost 144˙230 €
 EC max contribution 144˙230 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2016
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2017
 Duration (year-month-day) from 2017-05-01   to  2018-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS FR (PARIS) coordinator 144˙230.00

Map

 Project objective

Based on their antiviral and antitumor effect, type I interferons (IFNs) were believed to be the miracle drug to tackle viruses and cancer. However, clinical IFN applications remained limited due to severe side effects resulting from widespread cellular sensitivity to IFN, which limits the administrable doses. Hence, the drug concentration at the desired infection or tumor site is often too low to be fully therapeutic efficient. AcTaferon (Activated-by-Targeting interferon), co-developed by Prof. Uzé, circumvents these obstacles. By fusing an IFN mutant with strongly reduced receptor binding affinity to a targeting moiety that recognizes a surface marker on specific cells, AcTaferon remains inactive “en route” through the body and unveils its biological activity only on specific target cells. Robust tumor regression without side effects and preliminary antiviral effects underscore the huge clinical potential of AcTaferon to fight cancer and viral diseases. By combining the AcTaferon and influenza expertise of Prof. Uzé and Prof. Saelens, respectively, this interdisciplinary project offers the opportunity to broaden the innovative AcTaferon therapeutic strategy from the cancer to the viral infection field. Influenza A was selected as a pilot target as seasonal influenza A epidemics and occasional pandemics remain a serious health threat causing substantial morbidity and mortality. Influenza A-targeted AcTaferons will be developed and analyzed in relevant in vitro and in vivo models. Eventually, all knowledge will be transferred to Orionis, a company that will implement the AcTaferon technology to develop novel drugs. My background on the intracellular processes that negatively regulate cytokine receptors and hence influence the cellular sensitivity to a (therapeutic) cytokine is an asset to this project. I will be able to extend my fundamental research experience with applied cytokine research, which may extend into a new academic or industrial research pipeline.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ACTAFERON" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ACTAFERON" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

EGeoCC (2019)

Ethnic geography and civil conflict

Read More  

OPTIMAL-D (2019)

Development and Application of Mass Spectrometry Methods for Analysis of Optimal Vitamin D

Read More  

FARMACCOUNTA (2019)

Farm Accountancy Data as a Source for the History of European Agriculture

Read More